Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ketamine vs Methohexital Induction in ECT
NCT04022226Phase 1Completed
- Sponsor
- The University of New Mexico
- Start
- Oct 2019
- Primary completion
- Oct 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised trial of ketamine in major depressive disorder (MDD) and bipolar disorder (BD) (2 arms), sponsored by The University of New Mexico. Primary endpoint: Number of Participants Assessed for Clinical Efficacy of ECT at 1 year. Started Oct 2019; status: completed.
02
Drugs
ketamine
03
Conditions
major depressive disorder (MDD)bipolar disorder (BD)
Beyond the preview
Go deeper on NCT04022226.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04022226.